EXEL
Exelixis, Inc.
NASDAQ · Healthcare · Biotechnology · US
$59.01
−0.20%Sep 4, 2026, 15:54 UTC
Handa Biotechnology announced that its new anticancer drug HND-039 (Omcazio capsules) received final approval from the US FDA, allowing it to enter the US market, with the originator's patent expiring in late August and a citizen petition dismissed.
Source:Aug 31, 2026, 18:30 UTC
The U.S. Court of Appeals for the Federal Circuit affirmed a key portion of the 2024 District Court judgment in favor of Exelixis in its patent litigation against MSN Laboratories, upholding the decision that three patents covering Exelixis' product are valid and infringed.
Source:Aug 5, 2026, 20:05 UTC
Exelixis, Inc. reported its financial results for the second quarter of 2026 and provided a corporate update on its commercial, clinical, and pipeline development milestones.
Jun 23, 2026, 19:26 UTC
Exelixis reported clinical trial data for its drug zanzalintinib in colorectal cancer, which missed statistical significance in overall survival for a key subgroup.
Source: